Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Sep 11, 2026

Here are the stocks to favor in the fourth quarter — and those you should avoid

Large caps tend to outperform small caps as year's end approaches.

Market Watch • Sep 10, 2026

Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?

FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

Zacks Investment Research • Sep 9, 2026

NVST or ABT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Sep 9, 2026

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America ABBOTT PARK, Ill., Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib).

PRNewsWire • Sep 8, 2026

Here's Why Abbott (ABT) Fell More Than Broader Market

Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.

Zacks Investment Research • Sep 8, 2026

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

MarketBeat • Sep 6, 2026

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.

Zacks Investment Research • Sep 2, 2026

How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement

Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk.

Investors Business Daily • Aug 31, 2026

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers ABBOTT PARK, Ill., Aug. 31, 2026 /PRNewswire/ -- Parents looking for an infant formula made with whole milk now have a new option.

PRNewsWire • Aug 31, 2026